Last updated: March 8, 2026
What is the drug identified by NDC 60429-0633?
NDC 60429-0633 corresponds to Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor marketed as Imbruvica. Approved by the FDA since 2013, it is primarily used in the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström's macroglobulinemia, and other B-cell malignancies.
What is the current market landscape?
Market Size and Growth
- The global BTK inhibitor market was valued at approximately USD 7.1 billion in 2022.
- Compound Annual Growth Rate (CAGR): 10.4% from 2023 to 2030.
- Key driver: Rising incidence of B-cell cancers and increased adoption of targeted therapies.
Leading Competitors
| Company |
Drug Name |
Indications |
Market Share (2022) |
Launch Year |
| AbbVie/Biogen |
Imbruvica |
CLL, MCL, Waldenström’s |
approx. DOS |
2013 |
| AstraZeneca |
Calquence |
CLL, SLL |
estimated 10% |
2019 |
| BeiGene |
Brukinsa |
MCL, CLL, Waldenström’s |
emerging |
2019 |
| Johnson & Johnson |
Imbruvica |
CLL, MCL, WM |
dominant |
2013 |
Imbruvica leads due to early market entry, extensive approval spectrum, and established payer coverage.
Pricing Environment
- Average Wholesale Price (AWP): $8,400 per month (estimated for 2023).
- Patient Cost Share: Approximately 20-30%, depending on insurance.
- Reimbursement: Predominantly through commercial insurers and Medicare Part D.
Market Expansion Factors
- Expanded indications, including first-line treatments.
- Entry into emerging markets via licensing and local manufacturing.
- Increasing use as maintenance therapy post-chemotherapy.
What are the price projections?
Short-term (2024-2026)
- Price Stability: AWP likely remains around USD 8,200–8,600/month.
- Pricing pressures: Potential discounts from biosimilar or generic entrants post-patent expiry.
- Reimbursement trends: Consolidation in payer policies may influence patient access, keeping net prices stable or slightly decreasing.
Long-term (2027-2030)
- Patent Expiry: Expected around 2029–2030 based on primary patent status.
- Biosimilar Entry: Likely to reduce prices by 20–35%.
- Market Dynamics: Increased competition and price erosion expected as biosimilars and generics enter the market.
Potential Influences on Price Trends
- Policy changes favoring biosimilars and cost containment.
- Slow approval of next-generation BTK inhibitors that may offer efficacy benefits but at higher prices.
- Negotiation power of payers increasing, leading to value-based pricing models.
Regulatory and Patent Landscape
| Aspect |
Details |
| Patent Expiry |
Estimated 2029–2030 |
| Patent Challenges |
Several legal challenges and patent extensions possible |
| Regulatory Approvals |
Extended to multiple geographies, including Europe, Asia, and Latin America |
Market Entry and Development Opportunities
- Development of biosimilar versions could capture significant market share.
- Combination therapies with other targeted agents or immunotherapies.
- Expansion into off-label indications driven by clinical evidence.
Key Takeaways
- Imbruvica remains the market leader with stable prices for now.
- The market is highly competitive, with newer entrants and biosimilars poised to challenge pricing.
- Prices are projected to decline 20–35% within five years post-patent expiry.
- Market growth is driven by expanding indications and geographic penetration.
- Payer strategies and regulatory policies will significantly influence long-term pricing.
FAQs
1. When will patent expiry most likely lead to biosimilar entry?
Between 2029 and 2030, contingent on patent disputes and regulatory approvals.
2. How much could prices decrease post-biosimilar entry?
Average reductions range from 20% to 35%, depending on market share captured by biosimilars.
3. Which regions are expanding the fastest for Imbruvica?
Emerging markets such as China, Brazil, and India exhibit rapid growth due to increasing cancer prevalence and payer coverage.
4. What are the main drivers of Imbruvica’s market share?
Early FDA approval, extensive indication approval, established physician familiarity, and reimbursement pathways.
5. Are there upcoming competitors that could impact prices?
Yes, newer BTK inhibitors like Acalabrutinib (Calquence) and Zanubrutinib could influence pricing and market dynamics.
References
- Grand View Research. (2023). BTK inhibitor market size, share & trends analysis.
- IQVIA. (2022). U.S. prescription drug market report.
- U.S. Food and Drug Administration. (2013). FDA approval of Imbruvica.
- Frost & Sullivan. (2023). Global oncology drug market outlook.
- MarketWatch. (2023). Oncology drug pricing analysis and forecasts.
